Global results show 90% of patients are in favor of a saliva-based glucose test NEW YORK, June 08, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care,
- Anticipate Emergency Use Submission for SARS-CoV-2 Antibody Biosensor Test in the Second Half of 2021- - $14 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2021, Provides Runway into the Second Half of 2022 - - Established a Point-of-Care Test Commercialization
NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- GBS, Inc. (NasdaqGS: GBS), a life sciences company developing non-invasive, real-time point-of-care (POC) diagnostic tests, and the Wyss Institute for Biologically Inspired Engineering at Harvard University (Wyss Institute) have received approval from
NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company that develops non-invasive, real-time point of care (POC) diagnostic tests for patients and their primary health practitioners, today announced the execution of a sponsored research agreement with Johns
- December 2020 Initial Public Offering generated $21.6m in gross proceeds and listing on the NASDAQ Stock Market -Executes Partnerships, Research Collaboration and Commercial Agreements- - John Hopkins University, Wyss Institute & Cambridge Consultants Ltd. NEW YORK, Feb.
NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- GBS Inc. (the “Company”) (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of care, today announced the closing of its previously announced
Will Trade on the Nasdaq Global Market Under Ticker “GBS” NEW YORK, Dec. 23, 2020 (GLOBE NEWSWIRE) -- GBS Inc. (the “Company”) (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of
Will Trade on the Nasdaq Global Market Under Ticker “GBS” NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- GBS Inc. (the “Company”) (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of
The iQ Group Global has announced a collaboration with Harvard University to develop a printable point-of-care SARS-CoV-2 antibody test for the COVID-19 disease that could produce results in real-time. Life Science Biosensor Diagnostics Pty Ltd (LSBD), a development company of The iQ Group Global,
The iQ Group Global is pleased to announce that Life Science Biosensor Diagnostics Pty Ltd (LSBD) has commenced engagement with the US Food and Drug Administration (FDA) for the approval pathway of the Saliva Glucose Biosensor. On May 1 st , LSBD lodged a 513(g) submission, the first step to
